The Global Tocilizumab Market Size Was Valued at USD 81.19 Million in 2023 and is Projected to Reach USD 228.96 Billion by 2032, Growing at a CAGR of 12.20%. Tocilizumab (marketed primarily as Actemra) is a breakthrough therapeutic agent a humanized monoclonal antibody specifically designed to target the interleukin-6 (IL-6) receptor. By binding to this […]
Wo Markttrends auf informierte Entscheidungen treffen
Headline
Tag: Tocilizumab Growth
Back To Top